Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Aims to Become First Company with Dual Hong Kong and Shanghai Listings

publication date: May 5, 2019

Junshi Biosciences filed to IPO on Shanghai's new Technology & Innovation Exchange, after the company completed a $394 million Hong Kong IPO in December 2018. Junshi plans to list 10% of its shares in the IPO, which means the IPO would raise about $400 million before fees. It will be the first biopharma to have a dual Hong Kong/Shanghai High-Tech listing. Junshi did very well after its Hong Kong IPO, rising 65% from the IPO price. In January, Junshi was approved to launch its PD-1 immunotherapy, Tuoyi, for multiple myeloma. More details....

Stock Symbol: (HK: 1877; NEEQ: 833330)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital